BREAKING 🚨: Moderna$MRNA falls to its lowest closing price since the onset of Covid 📉📉 Shares down more than 95% since the 2021 all-time high – absolute collapse pic.twitter.com/z9HPsJhJaO
— Barchart (@Barchart) May 15, 2025
Moderna’s stock has suffered a staggering decline, closing at $23.65, its lowest price since the early days of the Covid pandemic. The biotech firm, once riding high on vaccine demand, has now lost more than 95% of its value since reaching an all-time high of $484.47 in August 2021.
The collapse reflects a dramatic shift in investor sentiment. During the height of the pandemic, Moderna’s mRNA vaccine was hailed as a breakthrough, driving its stock to record levels. As demand for Covid boosters waned and competition intensified, the company struggled to maintain momentum. Revenue projections have fallen sharply, and concerns over long-term profitability have spooked investors.
Biotech stocks are notoriously volatile, but Moderna’s decline stands out. The company’s 52-week high was $170.47, meaning shares have plunged over 85% in just one year. Analysts point to weak earnings reports, declining government contracts, and uncertainty surrounding future mRNA applications as key factors behind the selloff.
Sources:
https://www.macrotrends.net/stocks/charts/MRNA/moderna/stock-price-history
